BeOne Medicines names R&D chief Wang Lai as co-president to lead global expansion

Leadership Changes - BeOne Medicines has promoted Wang Lai to the newly created role of co-president, indicating a leadership expansion as the company advances its late-stage pipeline and globalization efforts [1] - Wang, who has been the global head of R&D since April 2021, will retain his R&D responsibilities while also overseeing business development and managing business alliance relationships starting January [2][4] Financial Performance - BeOne generated global revenue of approximately US$3.8 billion last year, a significant increase from US$1.4 billion in the previous year, driven by flagship products Brukinsa and Tevimbra [6] - Brukinsa achieved global sales of 18.7 billion yuan in 2024, ranking second globally and first in China in its class, contributing to the company's first profitable half-year in early 2024 [6] Product Development - Tevimbra, a PD-1 antibody treatment, has received regulatory approvals across the EU's 27 member states, Iceland, Norway, and 16 other countries in North America, Europe, and Asia-Pacific [7]